Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a pro-atrophy gene. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Application
Filed:
August 2, 2019
Publication date:
December 1, 2022
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Type:
Grant
Filed:
May 24, 2022
Date of Patent:
November 15, 2022
Assignee:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Application
Filed:
June 22, 2022
Publication date:
October 13, 2022
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to methods of purifying complexes comprising a protein (e.g., antibody) covalently linked to an oligonucleotide. In some embodiments, complexes comprising a protein covalently linked to an oligonucleotide are purified and isolated from unlinked oligonucleotide using an mixed-mode resin that comprises positively-charged metal sites and negatively charged ionic sites, e.g., hydroxyapatite resin. In some embodiments, complexes comprising a protein covalently linked to an oligonucleotide are purified from a mixture comprising the complexes, unlinked protein, and unlinked oligonucleotide using a purification step involving hydrophobic interaction chromatography resin followed by a purification step involving mixed-mode resin.
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Type:
Application
Filed:
May 24, 2022
Publication date:
September 15, 2022
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Grant
Filed:
February 15, 2022
Date of Patent:
July 19, 2022
Assignee:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Type:
Grant
Filed:
January 21, 2022
Date of Patent:
June 28, 2022
Assignee:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Application
Filed:
August 2, 2019
Publication date:
June 23, 2022
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Application
Filed:
February 15, 2022
Publication date:
June 2, 2022
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Type:
Application
Filed:
January 21, 2022
Publication date:
May 12, 2022
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Grant
Filed:
August 12, 2021
Date of Patent:
March 29, 2022
Assignee:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Type:
Grant
Filed:
October 14, 2021
Date of Patent:
February 15, 2022
Assignee:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Type:
Application
Filed:
October 14, 2021
Publication date:
January 27, 2022
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Application
Filed:
August 12, 2021
Publication date:
December 9, 2021
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Type:
Grant
Filed:
March 18, 2021
Date of Patent:
November 9, 2021
Assignee:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a MYH7 allele comprising a disease-associated mutation, e.g., for the treatment of hypertrophic cardiomyopathy. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Application
Filed:
August 2, 2019
Publication date:
October 21, 2021
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of ACVR1. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Application
Filed:
August 2, 2019
Publication date:
October 21, 2021
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DNM2. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Application
Filed:
August 2, 2019
Publication date:
October 21, 2021
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload reduces glycogen levels in a cell.
Type:
Application
Filed:
August 2, 2019
Publication date:
October 14, 2021
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Application
Filed:
August 2, 2019
Publication date:
October 7, 2021
Applicant:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins